AEterna Zentaris (AEZS) Rating Increased to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) from a hold rating to a buy rating in a report published on Tuesday. The firm currently has $2.75 price objective on the biopharmaceutical company’s stock.

According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. “

Separately, ValuEngine lowered AEterna Zentaris from a sell rating to a strong sell rating in a research note on Monday, September 17th. One research analyst has rated the stock with a sell rating and three have assigned a buy rating to the company. The company has an average rating of Buy and a consensus target price of $3.25.

Shares of AEZS stock opened at $2.37 on Tuesday. AEterna Zentaris has a 52-week low of $1.12 and a 52-week high of $3.25. The firm has a market capitalization of $36.66 million, a price-to-earnings ratio of -1.76 and a beta of 0.75.

AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last issued its quarterly earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.32) by $0.16. AEterna Zentaris had a return on equity of 20.71% and a net margin of 6.76%. The business had revenue of $0.17 million during the quarter. As a group, equities analysts expect that AEterna Zentaris will post 0.05 earnings per share for the current fiscal year.

About AEterna Zentaris

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications.

Read More: Stock Symbols and CUSIP Explained

Get a free copy of the Zacks research report on AEterna Zentaris (AEZS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with's FREE daily email newsletter.

Leave a Reply